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Background
In cancer immunotherapy, effector B cells can inhibit spon-
taneous tumor metastases as well as local tumor growth in
animal models. We have previously reported that anti-
tumor effector B cells generated from tumor-draining
lymph node (TDLN) could directly kill tumor cells via the
Fas/FasL pathway and are regulated by IL-10. As a result,
adoptive transfer of TDLN B cells conferred tumor regres-
sion in a spontaneous pulmonary metastasis mouse model
of breast cancer, 4T1. Removal of IL-10, either by using IL-
10-/- TDLN B cells or by systemic neutralization of IL-10
using anti-IL-10 antibody, significantly augmented the
therapeutic efficacy of adoptively transferred TDLN B cells.
Methods
The 4T1 cell line is a mammary carcinoma syngeneic to
BALB/c mice. 4T1 draining inguinal lymph nodes were
collected and cell suspension prepared. CD19+ B cells
were purified from the TDLN cells using MACS separa-
tor and were activated with LPS plus anti-CD40 mAb
ascites. Cell surface expression of CD19 and CXCR4
and CD25 were analyzed by immunofluorescence assay.
Healthy BALB/c mice were inoculated with 4T1 by s.c.
14 days after tumor inoculation, the mice were treated
with tail vein injection of activated 4T1 TDLN B cells
with or without IL-2 administration. 14 days after B cell
transfer, all mice were sacrificed, and lungs were har-
vested for enumeration of spontaneous pulmonary
metastatic nodules. The significance of differences in
numbers of metastatic nodules, and cell lysis was deter-
mined using one-way analysis of variance (Newman-
Keuls post hoc test) or unpaired Student’s t-test.
Results
Tumor cell death mediated by effector B cells involves
the CXCR4/CXCL12 as well as Fas/FasL interactions.
Blockade of CXCR4 and FasL using a CXCR4-specific
inhibitor, AMD3100, and anti-FasL antibody, respec-
tively, reduced the killing of 4T1 tumor cells by 4T1
TDLN B cells. Of note, blockade of CXCR4 and FasL
concurrently inhibited B cell-mediated direct killing of
tumor cells in an additive fashion, suggesting that both
CXCL12/CXCR4 and Fas/FasL pathways are involved in
the direct killing of 4T1 tumor cells by 4T1 TDLN B
cells. In other experiments, we found that TDLN B cells
express IL-2 receptors (IL-2R) and the ability of the
TDLN B cells to inhibit metastasis was significantly
enhanced with exogenous IL-2 administration.
Conclusions
Besides our previously reported Fas/FasL pathway and
IL-10-mediated suppression, our recently identified
CXCL12/CXCR4 pathway and IL-2-mediated augmenta-
tion of the biological function of effector B cells suggests
these B cells may represent an important component of
the host immune response against tumor.
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